Dasatinib worsens the effect of cetuximab in combination with fractionated radiotherapy in FaDu- and A431-derived xenografted tumours

BACKGROUND: Cetuximab is often combined with radiotherapy in advanced SCCHN. Alternative routes bypassing inhibition of EGFR with cetuximab may overshadow the efficacy of this combination. We undertook this study to investigate a possible role of dasatinib in this scenario. METHODS: The SCC5, SCC25,...

Descripción completa

Detalles Bibliográficos
Autores principales: Baro, M, de Llobet, L I, Figueras, A, Skvortsova, I, Mesia, R, Balart, J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2014
Materias:
Translational Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4183853/
https://www.ncbi.nlm.nih.gov/pubmed/25077442
http://dx.doi.org/10.1038/bjc.2014.432

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4183853/
https://www.ncbi.nlm.nih.gov/pubmed/25077442
http://dx.doi.org/10.1038/bjc.2014.432

Ejemplares similares